Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia

Sponsor
Fondazione Don Carlo Gnocchi ETS
Study ID
NCT07707245
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Peripheral Blood Collection — PROCEDURE
    Peripheral venous blood collection (approximately 40 mL) for inflammatory, immunological, genetic, and epigenetic biomarker analyses, including PBMC isolation, serum collection, genomic DNA extraction, and microRNA analysis.

Study Details

Primary Objective: To evaluate the association between inflammatory, immunological, genetic, and epigenetic biomarkers measured at enrollment and the clinical, functional, and phenotypic characteristics of patients with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer. Secondary Objective: To assess the prognostic value of the identified biomarkers by evaluating their ability to predict clinical outcomes at 12 months. Primary Outcome Measure: Association between baseline inflammatory, immunological, genetic, and epigenetic biomarkers and disease-specific clinical, functional, and phenotypic characteristics assessed at enrollment, including: COPD: current or former smokers, stratified according to the predominant phenotype (emphysema or bronchiolitis); IPF: rapid progressors, slow progressors, and patients with combined pulmonary fibrosis and emphysema (CPFE); Lung cancer: current smokers, former smokers who quit less than 15 years before enrollment, former smokers who quit 15 years or more before enrollment, and never-smokers. Secondary Outcome Measure: Predictive performance of baseline inflammatory, immunological, genetic, and epigenetic biomarkers for 12-month clinical outcomes.

Key Dates

First listed
Jul 16, 2026
Start date
Apr 22, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2027
Completion
Oct 30, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Biomarker Assessment
    Participants with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or resectable lung carcinoma will undergo peripheral blood collection at baseline for inflammatory, immunological, genetic, and epigenetic biomarker analyses. Clinical and functional data will be collected at baseline, and participants will undergo a 12-month follow-up to evaluate the prognostic value of the identified biomarkers.

Primary Outcome Measure

Innate immunity [ Time Frame: Baseline ]

Central Contacts

Find similar trials

Nationwide
COPD trialsLung cancer trialsPulmonology trialsLung disease trialsOncology trialsLung oncology trials

Related Studies